Suppr超能文献

原发性硬化性胆管炎患者的骨骼疾病。

Bone disease in patients with primary sclerosing cholangitis.

机构信息

Division of Digestive Diseases and Nutrition, University of Kentucky Medical Center, Lexington, Kentucky 40536, USA.

出版信息

Gastroenterology. 2011 Jan;140(1):180-8. doi: 10.1053/j.gastro.2010.10.014. Epub 2010 Oct 16.

Abstract

BACKGROUND & AIMS: Osteopenic bone disease occurs frequently among patients with chronic liver disease but has not been well studied in those with primary sclerosing cholangitis (PSC). We investigated the prevalence, rate of progression, and independent predictors of bone disease in a large number of patients with all stages of PSC.

METHODS

Bone mineral density of the lumbar spine, hip, and total body was measured yearly for 10 years in 237 patients with PSC.

RESULTS

Osteoporosis (T-score less than -2.5) was found in 15% of patients and occurred 23.8-fold (95% confidence interval [CI], 4.6-122.8) more frequently in those with PSC than expected from a matched population. By multivariate analysis, age 54 years or older (odds ratio [OR], 7.8; 95% CI, 3.3-18.3), body mass index ≤ 24 kg/m(2) (OR, 4.9; 95% CI, 1.9-12.6), and inflammatory bowel disease for ≥ 19 years (OR, 3.6; 95% CI, 1.5-8.4) correlated with the presence of osteoporosis. Osteoporosis was present in 75% of patients with all 3 risk factors but in only 3.1% of those without all of them. Patients with PSC lost 1% of bone mass per year; this rate of bone loss was significantly associated with duration of inflammatory bowel disease.

CONCLUSIONS

Osteoporosis occurs frequently among patients with PSC. Old age, low body mass index, and long duration of inflammatory bowel disease can be used to identify patients with PSC who might derive the most benefit from measurements of bone density and treatments for bone diseases.

摘要

背景与目的

骨质疏松症在慢性肝病患者中较为常见,但在原发性硬化性胆管炎(PSC)患者中尚未得到很好的研究。我们对大量不同阶段 PSC 患者进行了研究,以调查其骨病的患病率、进展速度和独立预测因素。

方法

对 237 例 PSC 患者每年进行腰椎、髋部和全身骨密度测量,共 10 年。

结果

骨质疏松症(T 评分低于-2.5)在 15%的患者中发现,与匹配人群相比,PSC 患者的发生率高 23.8 倍(95%置信区间[CI],4.6-122.8)。多变量分析显示,年龄 54 岁或以上(比值比[OR],7.8;95%CI,3.3-18.3)、体重指数≤24 kg/m2(OR,4.9;95%CI,1.9-12.6)和炎症性肠病≥19 年(OR,3.6;95%CI,1.5-8.4)与骨质疏松症的存在相关。所有 3 个危险因素均存在骨质疏松症的患者占 75%,而无 3 个危险因素的患者仅占 3.1%。PSC 患者每年骨质流失 1%;这种骨丢失率与炎症性肠病的持续时间显著相关。

结论

骨质疏松症在 PSC 患者中较为常见。高龄、低体重指数和炎症性肠病的持续时间较长可用于识别 PSC 患者,这些患者可能从骨密度测量和骨病治疗中获益最大。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c82/3043598/1ecb2f6f59f3/nihms246481f1.jpg

相似文献

1
Bone disease in patients with primary sclerosing cholangitis.原发性硬化性胆管炎患者的骨骼疾病。
Gastroenterology. 2011 Jan;140(1):180-8. doi: 10.1053/j.gastro.2010.10.014. Epub 2010 Oct 16.

引用本文的文献

2
Management of primary sclerosing cholangitis: Current state-of-the-art.原发性硬化性胆管炎的管理:当前的技术水平。
Hepatol Commun. 2024 Nov 15;8(12). doi: 10.1097/HC9.0000000000000590. eCollection 2024 Dec 1.
5
Emerging role of liver-bone axis in osteoporosis.肝-骨轴在骨质疏松症中的新作用
J Orthop Translat. 2024 Sep 4;48:217-231. doi: 10.1016/j.jot.2024.07.008. eCollection 2024 Sep.
7
Caring for the Bone Health Among Liver Transplant Recipients.关爱肝移植受者的骨骼健康。
J Clin Exp Hepatol. 2023 Nov-Dec;13(6):1130-1139. doi: 10.1016/j.jceh.2023.05.003. Epub 2023 May 12.
8
Current Therapeutics in Primary Sclerosing Cholangitis.原发性硬化性胆管炎的当前治疗方法
J Clin Transl Hepatol. 2023 Oct 28;11(5):1267-1281. doi: 10.14218/JCTH.2022.00068S. Epub 2023 Apr 17.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验